HK Stock Market Move | AI drug discovery enters the strategic entry phase. METIS TECHBIO-P (07666) rises over 11% to lead the sector, while INSILICO (03696) gains over 6%.

AI drug discovery concept stocks rose collectively. As of press time, METIS TECHBIO-P (07666) gained 11.33% to HK$17.29; XTALPI (02228) rose 7.32% to HK$7.4; INSILICO (03696) gained 6.05% to HK$57.0; GENSCRIPT BIO (01548) rose 5.16% to HK$39.14. On the news front, positive developments continue to emerge in the AI drug discovery sector. On September 16, market sources said that Anew Labs, the AI drug discovery business spun off from ByteDance, completed its first round of external financing, raising US$290 million at a post-money valuation of approximately US$1.5 billion; on the same day, GenScript announced a collaboration with Eli Lilly's AI/machine learning drug discovery collaboration platform Lilly TuneLab. In addition, Novo Nordisk and Anthropic announced a partnership under which the two parties will use Anthropic's AI models and Claude Science to support drug discovery and R&D. Soochow pointed out that global technology giants are deeply embedding themselves into biomedicine through different paths, and AI drug discovery has entered a strategic entry phase. The dry-wet closed loop is the core operational logic chain of AIDD, and wet experiments are irreplaceable. On the upstream demand side, segments such as gene synthesis, protein expression and purification, in vitro validation, and model animals are all systematically benefiting from the explosion of AI candidate molecules.